Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors

International Journal of Immunopathology and Pharmacology

Volumn 16, Issue 2 SUPPL., 2003, Pages 17-22

  Van der Bijl, P ^a   Van der Bijl Jr , P ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

COX 2 specific inhibitors (coxibs); Efficacy; Safety; Uses

Indexed keywords

CELECOXIB; CHLOROFORM; CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PROTON PUMP INHIBITOR; ROFECOXIB; UTERUS SPASMOLYTIC AGENT; VALDECOXIB;

ARACHIDONIC ACID METABOLISM; ARTHRITIS; COLON PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HOMEOSTASIS; HUMAN; HYPERTENSION; INHIBITION KINETICS; KIDNEY DYSFUNCTION; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTE DYSFUNCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0142058254     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Heyneman C.A., C. Lawless-Liday and G.C. Wall. 2000. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 60:555.
2. Vane J.R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New. Biol. 231:235.
3. Smith W.L. and A.L. DeWitt. 1995. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol. 15:179.
4. Wallace J.L. 1992. Prostaglandins, NSAIDs and cytoprotection. Gastroenterol. Clin. North Am. 21:631.
5. Vane J.R. and R.M. Botting. 1995. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 44:1.
6. Simmons D.L., D.B. Levy, Y. Yannoni, et al. 1989. Identification of a phorbol ester-repressible v-src.- inducible gene. Proc. Natl. Acad. Sci. USA. 86:1178.
7. Williams C.S. and R.N. Du Bois. 1996. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol. 270:G393.
8. Vane J.R. and R.M. Botting. 1998. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am. J. Med. 104(S):2.
9. Katz N. 2002. Coxibs: Evolving role in pain management. Semin. Arthritis Rheum. 32 (3 S 1):15.
10. Bensen W., A. Weaver, L. Espinoza, et al. 2002. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology 41:1008.
11. Deeks J.J., L.A. Smith and M.D. Bradley. 2002. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised trials. BMJ 325:607.
12. Jeske A.H. 2002. Selecting new drugs for pain control: evidence-based decisions or clinical impressions? J. Am. Dent. Assoc. 133:1052.
13. Daniels S.E., P.J. Desjardins, S. Talwalker, et al. 2002. The analgesic efficacy of valecoxib vs. oxycodone/acetaminophen after oral surgery. J. Am. Dent. Assoc. 133:611.
14. Daniels S.E., S. Talwalker, S. Torri, et al. 2002. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet. Gynecol. 100:350.
15. Tang J., S. Li, P.F. White, X. Chen, et al. 2002. Effect of parecoxib, a novel intravenous cyclooxygenase type inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology 96:1305.
16. Barton S.F., F.F. Langeland, M.C. Snabes, et al. 2002. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 97:306.
17. Lanas A. 2002. Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology 41(S):16.
18. Cantor S.B. 2002. Pharmacoeconomics of coxib therapy. J. Pain Manage. 24(1 S):S28.
19. Silverstein F.E., G. Faich, J.L. Goldstein, et al. 2000. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247.
20. Jackson L.M. and C.J. Hawkey. 2000. COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 59:1207.
21. Layton D., J. Riley, L.V. Wilton, et al. 2003. Safety profile of rofecoxib as used in general practice in England: result of a prescription-event monitoring study. Br. J. Clin. Pharmacol. 55:166.
22. Laine L., L.G. Connors, A. Reicin, et al. 2003. Serious lower gastrointestinal events with nonselective NSAID or coxib use. Gastroenterology 124:288.
23. LeLorier J., C. Bombardier, E. Burgess, et al. 2002. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. Can. J. Cardiol. 18:1301.
24. Giovanni M.G. and P. Giovanni. 2002. Do nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J. Nephrol. 15:480.
25. Howes L.G. and H. Krum. 2002. Selective cyclooxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug Saf. 25:829.
26. Bombardier C., L. Laine, A. Reicin, et al. 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343:1520.
27. Goodman S., T. Ma, M. Trindade, et al. 2002. COX-2 selective NSAID decreases bone ingrowth in vivo. J. Orthop. Res. 20:1164.
28. Endo K., K. Sairyo, S. Komatsubara, et al. 2002. Cyclooxygenase-2 inhibitor inhibits the fracture healing. J. Physiol. Anthropol. Appl. Human Sci. 21:235.
29. Subongkot S., D. Frame, W. Leslie, et al. 2003. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 23:9.
30. Steinbach G., P.M. Lynch, R.K. Phillips, et al. 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:1946.
31. Qadri S.S., J.H. Wang, K.C. Redmond, et al. 2002. The role of COX-2 inhibitors in lung cancer. Ann. Thorac Surg. 74:1648.
32. Singh B. and A. Lucci. 2002. Role of cyclooxygenase-2 in breast cancer. J. Surg. Res. 108:173.
33. Pasinetti G.M. 2002. Cyclooxygenase as a target for the antiamyloidogenic activity of nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurosignals 11:293.
34. Badie B., J.M. Schartner, A.R. Hagar, et al. 2003. Microglia cyclooxygenase-2 activity in experimental gliomas and possible role in cerebral edema formation. Clin. Cancer Res. 9:872.
35. Begay C.K. and A.J. Gandolfi. 2003. Late administration of COX-2 inhibitors minimize hepatic necrosis in chloroform induced liver injury. Toxicology 185:79.
36. Ma N., M.J. Szabolcs, J. Sun, et al. 2002. The effect of selective inhibition of cyclooxygenase (COX-2) acute cardiac allograft rejection. Transplantation 74:1528.
37. Milas L., K.A. Mason, Z. Liao, et al. 2003. Chemoradiotherapy: Emerging treatment improvement strategies. Head Neck 25:152.
38. Hayes E.C. and J.A. Rock. 2002. COX-2 inhibitors and their role in gynecology. Obstet. Gynecol. Surv. 57:768.